219 related articles for article (PubMed ID: 31776278)
1. Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.
Easterhoff D; Pollara J; Luo K; Tolbert WD; Young B; Mielke D; Jha S; O'Connell RJ; Vasan S; Kim J; Michael NL; Excler JL; Robb ML; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Wiehe K; Saunders KO; Montefiori DC; Tomaras GD; Moody MA; Pazgier M; Haynes BF; Ferrari G
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776278
[TBL] [Abstract][Full Text] [Related]
2. Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial.
Tolbert WD; Van V; Sherburn R; Tuyishime M; Yan F; Nguyen DN; Stanfield-Oakley S; Easterhoff D; Bonsignori M; Haynes BF; Moody MA; Ray K; Ferrari G; Lewis GK; Pazgier M
mBio; 2020 Jun; 11(3):. PubMed ID: 32605979
[TBL] [Abstract][Full Text] [Related]
3. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
4. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
Easterhoff D; Moody MA; Fera D; Cheng H; Ackerman M; Wiehe K; Saunders KO; Pollara J; Vandergrift N; Parks R; Kim J; Michael NL; O'Connell RJ; Excler JL; Robb ML; Vasan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Liao HX; Ferrari G; Seaman MS; Montefiori DC; Tomaras GD; Harrison SC; Haynes BF
PLoS Pathog; 2017 Feb; 13(2):e1006182. PubMed ID: 28235027
[TBL] [Abstract][Full Text] [Related]
5. Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001.
Costa MR; Pollara J; Edwards RW; Seaman MS; Gorny MK; Montefiori DC; Liao HX; Ferrari G; Lu S; Wang S
J Virol; 2016 Nov; 90(22):10362-10378. PubMed ID: 27630232
[TBL] [Abstract][Full Text] [Related]
6. HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.
Easterhoff D; Pollara J; Luo K; Janus B; Gohain N; Williams LD; Tay MZ; Monroe A; Peachman K; Choe M; Min S; Lusso P; Zhang P; Go EP; Desaire H; Bonsignori M; Hwang KK; Beck C; Kakalis M; O'Connell RJ; Vasan S; Kim JH; Michael NL; Excler JL; Robb ML; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Wiehe K; Saunders KO; Montefiori DC; Tomaras GD; Moody MA; Arthos J; Rao M; Joyce MG; Ofek G; Ferrari G; Haynes BF
JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31996483
[TBL] [Abstract][Full Text] [Related]
7. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.
Acharya P; Tolbert WD; Gohain N; Wu X; Yu L; Liu T; Huang W; Huang CC; Kwon YD; Louder RK; Luongo TS; McLellan JS; Pancera M; Yang Y; Zhang B; Flinko R; Foulke JS; Sajadi MM; Kamin-Lewis R; Robinson JE; Martin L; Kwong PD; Guan Y; DeVico AL; Lewis GK; Pazgier M
J Virol; 2014 Nov; 88(21):12895-906. PubMed ID: 25165110
[TBL] [Abstract][Full Text] [Related]
8. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M
J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162
[TBL] [Abstract][Full Text] [Related]
9. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
Akapirat S; Karnasuta C; Vasan S; Rerks-Ngarm S; Pitisuttithum P; Madnote S; Savadsuk H; Rittiroongrad S; Puangkaew J; Phogat S; Tartaglia J; Sinangil F; de Souza MS; Excler JL; Kim JH; Robb ML; Michael NL; Ngauy V; O'Connell RJ; Karasavvas N;
PLoS One; 2018; 13(4):e0196397. PubMed ID: 29702672
[TBL] [Abstract][Full Text] [Related]
10. Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.
Dennison SM; Anasti KM; Jaeger FH; Stewart SM; Pollara J; Liu P; Kunz EL; Zhang R; Vandergrift N; Permar S; Ferrari G; Tomaras GD; Bonsignori M; Michael NL; Kim JH; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Liao HX; Haynes BF; Alam SM
J Virol; 2014 Aug; 88(16):9406-17. PubMed ID: 24920809
[TBL] [Abstract][Full Text] [Related]
11. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
Front Immunol; 2020; 11():719. PubMed ID: 32411138
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.
Pollara J; Bonsignori M; Moody MA; Liu P; Alam SM; Hwang KK; Gurley TC; Kozink DM; Armand LC; Marshall DJ; Whitesides JF; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; O'Connell RJ; Kim JH; Michael NL; Montefiori DC; Tomaras GD; Liao HX; Haynes BF; Ferrari G
J Virol; 2014 Jul; 88(14):7715-26. PubMed ID: 24807721
[TBL] [Abstract][Full Text] [Related]
13. Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.
Bruel T; Guivel-Benhassine F; Lorin V; Lortat-Jacob H; Baleux F; Bourdic K; Noël N; Lambotte O; Mouquet H; Schwartz O
J Virol; 2017 Apr; 91(8):. PubMed ID: 28122982
[TBL] [Abstract][Full Text] [Related]
14. Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.
Williams LD; Shen X; Sawant SS; Akapirat S; Dahora LC; Tay MZ; Stanfield-Oakley S; Wills S; Goodman D; Tenney D; Spreng RL; Zhang L; Yates NL; Montefiori DC; Eller MA; Easterhoff D; Hope TJ; Rerks-Ngarm S; Pittisuttithum P; Nitayaphan S; Excler JL; Kim JH; Michael NL; Robb ML; O'Connell RJ; Karasavvas N; Vasan S; Ferrari G; Tomaras GD;
PLoS Pathog; 2023 May; 19(5):e1011359. PubMed ID: 37256916
[TBL] [Abstract][Full Text] [Related]
15. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG.
Md Zahid H; Kuwata T; Takahama S; Kaku Y; Biswas S; Matsumoto K; Tamamura H; Matsushita S
Retrovirology; 2021 Aug; 18(1):23. PubMed ID: 34419098
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects.
Dupuy FP; Kant S; Barbé A; Routy JP; Bruneau J; Lebouché B; Tremblay C; Pazgier M; Finzi A; Bernard NF
mBio; 2019 Dec; 10(6):. PubMed ID: 31848282
[TBL] [Abstract][Full Text] [Related]
19. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen.
Wang Q; Dai Y; Sun Z; Su X; Yu Y; Hua C; Xu W; Jiang S; Lu L
Emerg Microbes Infect; 2017 Nov; 6(11):e102. PubMed ID: 29184156
[No Abstract] [Full Text] [Related]
[Next] [New Search]
